Pfizer Inc. Press Releases https://investors.pfizer.com/generated by Q4Sat, 17 Oct 2026 18:28:30 -0400Copyright Q4 Inc. All rights reserved.Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 202615286fba-123a-4035-ba47-65165475aedchttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Showcases-Clinical-Advancements-Across-Infectious-Diseases-at-IDWeek-2026/default.aspxWed, 14 Oct 2026 06:45:00 -0400Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer369480f0-091f-41aa-8d89-38e9e783d79ehttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizers-TUKYSA-Regimen-Receives-FDA-Approval-as-Front-Line-Maintenance-Treatment-for-HER2-Metastatic-Breast-Cancer/default.aspxWed, 07 Oct 2026 12:57:00 -0400Pfizer Declares Fourth-Quarter 2026 Dividend930415f1-ef03-4b41-a799-8b30bc22f97chttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Declares-Fourth-Quarter-2026-Dividend/default.aspxTue, 06 Oct 2026 10:00:00 -0400Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligoadf4fe92-3d05-4874-bd19-54f8644cf0echttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizers-LITFULO-Significantly-Improved-Facial-and-Total-Body-Repigmentation-in-Patients-with-Nonsegmental-Vitiligo/default.aspxFri, 02 Oct 2026 11:15:00 -0400Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Studyfb48ef55-84c1-40fa-9e9a-cb97464fd73bhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizers-Tilrekimig-Shows-Significant-Skin-Clearance-in-Phase-2-Atopic-Dermatitis-Study/default.aspxThu, 01 Oct 2026 02:30:00 -0400Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMOf3709c9f-05ff-41f5-b6a7-eb8494daa4c5https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Advances-Todays-Cancer-Care-and-Tomorrows-Potential-Breakthroughs-at-ESMO/default.aspxMon, 28 Sep 2026 06:45:00 -0400Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts70c58d92-bbab-49b9-92cb-5788a3196f32https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-November-3-Conference-Call-with-Analysts/default.aspxTue, 22 Sep 2026 10:00:00 -0400Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference494d6074-5128-4483-a612-448f2fc2aae9https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference-b93cc0008/default.aspxTue, 15 Sep 2026 10:00:00 -0400Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conferenced3b0eac9-53fd-4494-bfe9-66b4afae10achttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference-7d792aa0c/default.aspxTue, 08 Sep 2026 10:00:00 -0400Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine9f1a7350-7ae0-44c6-b904-e96a40f8104bhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-and-BioNTech-Receive-U-S--FDA-Approval-for-XFG-adapted-COVID-19-Vaccine/default.aspxThu, 27 Aug 2026 16:30:00 -0400